Effects of Gnrh Agonist and Gnrh Antagonist Stimulation Protocols on Oxidative Stress Status in Follicular Fluid of Women Undergoing IVF: Results from A Large, Prospective, Single-Center Analysis
Main Article Content
Abstract
Objective: The aim of our study was to evaluate the impact of GnRH agonist and GnRH antagonist stimulation protocols on the level of oxidative stress in the follicular fluid of women who are undergoing in vitro fertilization (IVF). Our goal was to help clinicians choose the most suitable protocol that causes minimal oxidative stress while achieving successful IVF outcome.
How stimulation technique affect Lipid Peroxidation Malondialdehyde (MDA), Trolox Equivalent Antioxidant Capacity (TEAC), Super Oxide Dismutase (SOD), and Catalase in follicular fluid and IVF results in 102 women who underwent In Vitro Fertilization (IVF) at the Center of Obstetrics and Genecology IBN ROCHD Constantine, Algeria. During ovum pick-up, follicular fluid was collected to evaluate oxidative stress indicators such as SOD, Catalase, MDA, and TEAC.
The subjects who received the antagonist protocol had higher levels of SOD than those who received GnRHa protocols in the GnRHa group, the mean concentrations of FFSOD(3,60± 1,50 UI/ml/mg Protein vs 4,48± 1,17UI/ml/mg Protein; p<0.002), Catalase (2,03± 1,35 vs 2,99±2,00 U/mg Protein; p =0.015) .
In GNRH-a, the mean concentration of FF MDA (1, 09±0, 51 nMole/l vs0, 87±0, 36 nMole/l; p=0,008).
Compared to the other group, the antagonist protocol had the lowest average level of MDA.
In comparison to the antagonist protocol, the GnRHa protocol had a higher mean TEAC value.
The results showed that the changes in MDA were significant, but they were much lower in the antagonist groups compared to the agonist protocol, with a statistical significance of p=0.008
Conclusion:
The study has provided evidence that altering the protocol of ovarian stimulation leads to a variation in the level of oxidative stress parameters. The antagonist groups had significantly lower levels of MDA than those following the agonist protocol